"The Company has filed an additional ODD for the US Market for moderate to severe TBI, which if
granted in 2H CY2023 will provide seven years market exclusivity for Exenatide, certain tax credits
and a waiver from the Prescription Drug User Fee Act (PDUFA) fees, which were approximately
US$3.1 million in 2022. A proof of concept clinical trial for Exenatide to lower ICP in moderate to
severe TBI is under consideration."
This seems to be the key part from the 4C comments.
- Forums
- ASX - By Stock
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
"The Company has filed an additional ODD for the US Market for...
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IXC (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.0¢ |
Change
-0.007(10.5%) |
Mkt cap ! $4.509M |
Open | High | Low | Value | Volume |
6.0¢ | 6.0¢ | 6.0¢ | $3.264K | 54.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 600 | 6.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.0¢ | 20000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 600 | 0.060 |
1 | 15002 | 0.052 |
2 | 410000 | 0.051 |
1 | 200000 | 0.050 |
1 | 60001 | 0.041 |
Price($) | Vol. | No. |
---|---|---|
0.070 | 20000 | 1 |
0.077 | 7950 | 1 |
0.078 | 20000 | 1 |
0.081 | 888 | 1 |
0.083 | 5724 | 2 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
IXC (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online